Created at	Source	Raw Value	Validated value
June 25, 2024, noon	usa	* occurrence of a serious adverse event (death, anaphylactic shock, ...). * subjects wishing to withdraw from the study. * occurrence of a sars-cov-2 symptomatic infection during the follow-up period.	* occurrence of a serious adverse event (death, anaphylactic shock, ...). * subjects wishing to withdraw from the study. * occurrence of a sars-cov-2 symptomatic infection during the follow-up period.
Jan. 2, 2023, noon	usa	occurrence of a serious adverse event (death, anaphylactic shock, ...). subjects wishing to withdraw from the study. occurrence of a sars-cov-2 symptomatic infection during the follow-up period.	occurrence of a serious adverse event (death, anaphylactic shock, ...). subjects wishing to withdraw from the study. occurrence of a sars-cov-2 symptomatic infection during the follow-up period.